In a podcast, André Zimmermann explains what the MDR is all about and answers this question: “Is Europe and its MDR killing Medtech Innovation? “. EIT Health is an EU-funded “Knowledge and Innovation Community of the European Institute of Innovation and Technology (EIT)”. Its aim is to promote high-performance health systems and a sustainable health […]

SHS offers students from various disciplines the opportunity to complete an internship during their studies. In this way, SHS gives young, motivated people a practical insight into the areas of growth capital and private equity. SHS sees this as an important contribution to the professional development of future top performers. We are pleased to welcome […]

numares AG, a leader in NMR metabolomics-based diagnostics, has developed a novel multi-marker approach – GFRNMR – to determine kidney function using simple serum tests. The combination of multiple renal biomarkers can exceed the diagnostic limitations of the established method for estimating GFR (glomerular filtration rate). The assessment of kidney function is extremely important for […]

“OPN-NC Super High Pressure PTCA-Balloon” is the name of the high-pressure balloon catheter from the Swiss company SIS Medical AG, which achieved comparable, often even higher stent expansion compared to conventional balloon catheters in a successfully completed study on 74 heart patients. At the same time, the treatment success can be achieved in only one […]

After leading the Balingen-based homecare specialist medigroba GmbH on an impressive growth course over the past five years, SHS is now selling the company to Löwenstein Group. The medigroba management is confident that it will be able to continue on its successful course within Löwenstein Group, because there are more and more people who are […]

In the first part of the series ESG Investing (Environment, Social, Governance), Dr. André Zimmermann, Partner and Head of ESG at SHS, wrote about the basic principles of socially responsible investing. Today, we will take a closer look at how SHS implements ESG and SRI (Socially Responsible Investing) in concrete terms. Since its foundation almost […]

Chronic back pain is one of the most common pains in industrial societies; and sometimes it is so unbearable that only surgery with a spinal implant can help. Blue Ocean Spine GmbH is developing new types of spinal implants that can be individually adapted in situ, some of which even manage without additional screw fixation. […]

In future, we will introduce the SHS senior advisors to you here. The experience of these experts plays an important role for us in the investment process and benefits not least our portfolio companies. After completing his engineering studies, Heinz Jacqui worked for many years in top management positions at globally successful medium-sized companies. Most […]

The German Pain Society estimates the number of chronic pain patients in Germany alone at around 23 million people. These include, for example, cancer patients who suffer from severe, chronic pain that can usually only be treated with opioid analgesics. For these patients, among others, the SHS portfolio company Develco Pharma develops and produces orally […]

Unquote reports on the sale of homecare specialist Medigroba to the Löwenstein Group. The deal is SHS’s second exit of 2021; the GP sold its stake in Crystal LaserSystems to Silver Investment Partners in March 2021. SHS expects to launch fundraising for its next fund later in 2021.

In the course of a successful succession arrangement, Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH sells its shares in medigroba GmbH to Löwenstein Group With SHS as majority shareholder, medigroba has more than doubled revenue and tripled EBITDA in the last four and a half years Due to the continuing trend towards outpatient care, the medium-sized […]

ESG, SRI, impact investing: when did this start, and what is its importance in the healthcare sector?